Abeona Therapeutics Inc. announced the first commercial patient treatment with ZEVASKYN (prademagene zamikeracel), the first FDA-approved autologous gene therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN uses a patient's own skin cells, genetically modified to produce functional type VII collagen, addressing the underlying cause of RDEB and promoting wound healing. The therapy demonstrated clinically meaningful wound healing and pain reduction after a single surgical application. The results were announced as part of the launch of commercial treatment, with additional patients scheduled for treatment in the near future.